Get started
Author

David A. Irvine

Observed names: D A Irvine, D. Irvine, David A Irvine, David Irvine, Irvine, D.
Observed institutions: NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, Vancouver General Hospital, Queen Elizabeth University Hospital, University of Glasgow
OpenAlex ID: A5113487949
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
2024 · Mark J. Levis, Mehdi Hamadani, et al. · Journal of Clinical Oncology · 225
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
2023 · Claire Roddie, Lorna Neill, et al. · Blood Advances · 156
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
2021 · Claire Roddie, Juliana Dias, et al. · Journal of Clinical Oncology · 146
PDF
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
2013 · Kimberly Cramer-Morales, Margaret Nieborowska-Skorska, et al. · Blood · 145
Targeting hedgehog in hematologic malignancy
2012 · David A. Irvine, Mhairi Copland · Blood · 139
PDF
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
2016 · David A. Irvine, Bin Zhang, et al. · Scientific Reports · 78
PDF
Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma
2023 · Claire Roddie, Lazaros J. Lekakis, et al. · Blood · 74
PDF
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
2020 · Ross Kinstrie, Gillian A. Horne, et al. · Leukemia · 67
PDF
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial
2024 · Kate Cwynarski, Gloria Iacoboni, et al. · Nature Medicine · 45
Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.
2020 · Wendy Osborne, Maria Marzolini, et al. · Journal of Clinical Oncology · 42
Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
2019 · Andrea Kuhnl, Claire Roddie, et al. · Blood · 34
Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation
2012 · Krzysztof Flis, David Irvine, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 34
First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
2022 · Kate Cwynarski, Gloria Iacoboni, et al. · Blood · 27
Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells.
2009 · David A Irvine, Bin Zhang, et al. · Blood · 24
The role of the bone morphogenetic proteins in leukaemic stem cell persistence
2014 · Parto Toofan, David Irvine, et al. · Biochemical Society Transactions · 21
Inhibition of Chronic Myeloid Leukemia Stem Cells by the Combination of the Hedgehog Pathway Inhibitor LDE225 with Nilotinib
2010 · Bin Zhang, David Irvine, et al. · Blood · 18
Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors – A synthesis of clinical and laboratory data
2009 · David A. Irvine, Nicholas B. Heaney, et al. · Blood Reviews · 12
CD93 Is a Novel Biomarker of Leukemia Stem Cells in Chronic Myeloid Leukemia
2015 · Ross Kinstrie, Gillian A. Horne, et al. · Blood · 11
First in Human Study of Auto4, a Trbc1‐tragetting Cart T Cell Therapy in Relapsed/refractory Trbc1‐positive Peripheral T‐cell Lymphoma
2023 · K. Cwynarski, G. Iacoboni, et al. · Hematological Oncology · 8
PDF
Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study
2011 · Paolo Gallipoli, Pat Shepherd, et al. · British Journal of Haematology · 7
High-Dose Chemotherapy in Relapsed or Refractory Metastatic Germ-Cell Cancer: The Scotland Experience
2018 · Yun Yi Tan, Bahaa Al-Bubseeree, et al. · Clinical Genitourinary Cancer · 6
Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)
2023 · Claire Roddie, Eleni Tholouli, et al. · Blood · 5
Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis
2022 · Kathleen P. L. Cheok, Amy A. Kirkwood, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 5
PDF
The combination of hedgehog pathway inhibitor LDE225 and nilotinib eliminates chronic myeloid leukemia stem and progenitor cells
2010 · David Irvine, Bin Zhang, et al. · F1000Research · 5
Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics
2023 · Kathleen P. L. Cheok, Amy A. Kirkwood, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4
PDF
Works count: 43
Citation count: 1,358
H-index: 16
I10-index: 18
Year
Topic
Type